Lynparza (olaparib)

References

  1. Lynparza 100mg and 150mg film-coated tablets Summary of Product Characteristics.
    https://www.medicines.org.uk/emc/product/9204/smpc. [October 2019]. Accessed July 2020.
  2. NICE. NICE guidance on olaparib for maintenance treatment of ovarian, fallopian tube or peritoneal cancer that has a BRCA germline mutation after response to first-line platinum-based chemotherapy.
    https://www.nice.org.uk/guidance/indevelopment/gid-ta10257. [August 2019]. Accessed July 2020.
  3. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer TA620 | Guidance and guidelines | NICE. https://www.nice.org.uk/guidance/ta620. [January 2020]. Accessed July 2020.
  4. Scottish Medicines Consortium. Olaparib 100mg and 150mg film-coated tablets (Lynparza). SMC No. (2209).
    https://www.scottishmedicines.org.uk/media/4940/olaparib-lynparza-final-november-2019- for-website.pdf. [November 2019]. July 2020.
  5. Scottish Medicines Consortium. Re-submission - olaparib, 50mg, hard capsules (Lynparza). SMC No. (1047/15).
    https://www.scottishmedicines.org.uk/files/advice/olaparib_Lynparza_Resub_FINAL_Oct_2016_revised_201016_for_ website.pdf. [October 2016]. Accessed July 2020.
  6. Lynparza 50 mg hard capsules Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/6821/smpc. [October 2019]. Accessed July 2020.
  7. Moore, K. et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
  8. Capoluongo, E. et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Semin. Oncol. 44, 187–197 (2017).
  9. Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 21, 3194–3200 (2003).
  10. Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).
  11. Bookman, M. A. et al. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. J. Clin. Oncol. 27, 1419–1425 (2009).
  12. Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011).
  13. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).
  14. Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
  15. Moore, K. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. Supplementary appendix. N.Engl. J. Med. 379, (2018).
  16. Moore, K. et al. 2018. Oral presentation LBA7_PR, ESMO.
  17. Ledermann, J. et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
  18. Friedlander, M. et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br. J. Cancer 119, 1075–1085 (2018).
  19. Friedlander, M. & Matulonis, U. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy (Supplementary appendix). Br. J. Cancer 119, Appendix (2018).
  20. Robson, M. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 377, 523–533 (2017).